The use of sorafenib in HCC patients, a multi-tyrosine kinase inhibitor, targeting membrane receptors involved in angiogenic and mitogenic intra-cellular signaling and kinases along RAS/RAF/MEK/ERK pathway, offers a new approach of HCC therapy, which is molecular targeted therapy[8], [9]. The gene discussed is MAP2K7; the disease is hepatocellular carcinoma.